Mount Sinai researchers identified genes that predict a positive response to selinexor, a multiple myeloma therapy which can have serious side effects for some patients.
Researchers from the Dana-Farber Cancer Institute and the Tisch Cancer Institute at Mount Sinai Medical School showed that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care in 2021, although patient recruitment increased in 2021.
A multi-institutional study led by UNC Lineberger Comprehensive Cancer Center researchers found that diagnostic mammography results vary across racial and ethnic groups, with the rate of diagnostic accuracy highest in non-Hispanic white women and lowest in Hispanic women.
Results from the ELIANA pivotal clinical trial showed the long-term benefit of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with a maximum survival follow-up of 5.9 years.
Five-year follow-up results from the phase III CLL14 trial demonstrated that over 60% of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus Gazyva (obinutuzumab) continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment.
The ongoing, open-label, single-arm, pivotal phase II FIREFLY-1 clinical trial, evaluating DAY101 (tovorafenib) as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma, yielded positive initial data from the first 22 patients enrolled.
NXP900 yielded positive data in a preclinical xenograft model of group 4 medulloblastoma.
People with advanced cancer who communicated their symptoms weekly using an electronic survey had about a one-third better physical function and over a 15% better control of their symptoms compared to those who were evaluated less frequently via in-person clinical visits, according to findings from a multi-state study conducted at 52 community cancer clinics.
Researchers from the Parker Institute for Cancer Immunotherapy network identified certain patients with pancreatic cancer who may be more likely to benefit from combination treatment regimens consisting of immunotherapy and chemotherapy.
Positive data from a pivotal phase II/III trial for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (QUILT 3032) and phase II trial in advanced pancreatic cancer (QUILT 88) were announced at the 2022 ASCO annual meeting.